Literature DB >> 31597029

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply.

Talia Golan1, Gershon Y Locker2, Hedy L Kindler3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31597029     DOI： 10.1056/NEJMc1911185

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.

Authors:  Michael J Pishvaian; Edik M Blais; Jonathan R Brody; Emily Lyons; Patricia DeArbeloa; Andrew Hendifar; Sam Mikhail; Vincent Chung; Vaibhav Sahai; Davendra P S Sohal; Sara Bellakbira; Dzung Thach; Lola Rahib; Subha Madhavan; Lynn M Matrisian; Emanuel F Petricoin
Journal:  Lancet Oncol       Date:  2020-03-02       Impact factor: 41.316

Review 2.  Developing effective combination therapy for pancreatic cancer: An overview.

Authors:  Aubrey L Miller; Patrick L Garcia; Karina J Yoon
Journal:  Pharmacol Res       Date:  2020-03-02       Impact factor: 7.658

3.  WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.

Authors:  Amanpreet Kaur; Jun Yi Stanley Lim; Sugunavathi Sepramaniam; Siddhi Patnaik; Nathan Harmston; May Ann Lee; Enrico Petretto; David M Virshup; Babita Madan
Journal:  EMBO Mol Med       Date:  2021-03-04       Impact factor: 12.137

4.  Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance.

Authors:  Joaquina Martínez-Galán; Isabel Rodriguez; Octavio Caba
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.